Tabrecta is a medicine used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC), when the cancer is advanced and its cells have particular genetic mutations (changes) leading to \u2018mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping\u2019. This means that the cancer cells make an abnormal form of a protein called MET, because a part of the MET gene known as exon 14 is not used.<\/p>\n
Tabrecta is used when the patient needs further treatment after receiving immunotherapy or platinum-based chemotherapy, or both. Tabrecta contains the active substance capmatinib.<\/p>\n
To access capmatinib tablets sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj)<\/p>\n
Tabrecta (capmatinib) is a medication used for the treatment of adults with metastatic NSCLC with a mutation that leads to MET exon 14 skipping (METex14).<\/p>\n
Facts about capmatinib tablets<\/strong><\/p>\n Disease Indications-Lung Cancer If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import “capmatinib tablets\u201d based on the information you provide.<\/strong><\/p>\n
\nManufacturer-Novartis Pharmaceuticals Corporation
\nUsage-Oral
\nMedicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Pharmaceuticals and Medical Devices Agency (PMDA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n